By targeting the miR-19a-3p-HBP1-MIF pathway, HOTAIR represents a potential therapeutic target for modulating the inflammatory response and foam cell formation, offering promising avenues for the development of novel treatments for atherosclerosis. This evidence concerns the gene HBP1 and atherosclerosis.